<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405807</url>
  </required_header>
  <id_info>
    <org_study_id>AL1.1</org_study_id>
    <secondary_id>2009-017087-17</secondary_id>
    <nct_id>NCT01405807</nct_id>
  </id_info>
  <brief_title>Alemtuzumab for ANCA Associated Refractory Vasculitis</brief_title>
  <acronym>ALEVIATE</acronym>
  <official_title>Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overview:

      This open label, randomized, multi-centre study will enroll and treat 24 patients with
      refractory AAV.

      Aims:

      To determine the clinical response and severe adverse event rates associated with alemtuzumab
      therapy among patients with relapsing or refractory ANCA associated vasculitis (AAV).

      Hypothesis:

      Treatment with alemtuzumab induces sustained remission in AAV and will reduce
      immunosuppressive and steroid exposure.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a vasculitis response at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Response includes patients in complete and partial remission. Complete remission (CR) is defined as a BVAS/WG of 0 for at least one month. Partial response (PR) is the absence of severe BVAS/WG items and at least 50% fall in BVAS/WG score from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with a severe adverse event</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with treatment failure</measure>
    <time_frame>12 months</time_frame>
    <description>Treatment failure is defined as the failure to achieve a vasculitis response by six months or a vasculitis relapse between 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined damage assessment (CDA) scores</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non severe adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of corticosteroids</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to remission</measure>
    <time_frame>6 months</time_frame>
    <description>Complete and partial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Vasculitis</condition>
  <condition>Microscopic Polyangiitis</condition>
  <condition>Granulomatosis With Polyangiitis</condition>
  <condition>Wegener's</condition>
  <arm_group>
    <arm_group_label>Alemtuzumab - high dose (60mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alemtuzumab 30mg will be administered on Day 1 and Day 2 at 0 and 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alemtuzumab - low dose (30mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alemtuzumab 15mg will be administered on Day 1 and Day 2 at 0 and 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Alemtuzumab will be administered on Day 1 and Day 2 at 0 and 6 months</description>
    <arm_group_label>Alemtuzumab - high dose (60mg)</arm_group_label>
    <arm_group_label>Alemtuzumab - low dose (30mg)</arm_group_label>
    <other_name>Campath 1H</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A diagnosis of AAV, according to a standardized definition

          2. Active vasculitis with at least one severe or three non severe items of BVAS/WG
             activity (equivalent to BVAS/WG&gt;3)

          3. Previous therapy with either cyclophosphamide or methotrexate, in combination with
             prednisolone for at least 3 months.

        Exclusion Criteria:

          1. Age less than 18 or greater than 60 years

          2. Creatinine &gt; 150Î¼mol/l (1.7mg/dl)

          3. Total white count &lt; 4x109/l or lymphocyte count &lt; 0.5x109/l, or IgG &lt; 5g/L, or
             neutrophil count &lt; 1.5x109/l.

          4. Severe lung haemorrhage with hypoxia (&lt;85% on room air)

          5. Severe gastrointestinal, central nervous system or cardiac vasculitis

          6. Previous therapy with:

               1. Alemtuzumab at any time

               2. IVIg, infliximab, etanercept, adalimumab, abatacept, anti-thymocyte globulin or
                  plasma exchange in past three months

               3. Rituximab within the past 6 months

          7. Intensive care unit requirement

          8. Active infection with HIV, hepatitis B or hepatitis C or other infection requiring
             parenteral or long-term oral antibiotics

          9. History of ITP or platelet count at screening below 50,000 x 106/l

         10. Pregnancy or inadequate contraception in pre-menopausal women

         11. Breast feeding

         12. Any condition judged by the investigator that would cause the study to be detrimental
             to the patient.

         13. Any other multisystem autoimmune disease including Churg Strauss angiitis, systemic
             lupus erythematosus, anti-GBM disease and cryoglobulinaemia

         14. Any previous or current history of malignancy (other than resected basal cell
             carcinoma)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David RW Jayne, MD MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David RW Jayne, MD FRCP</last_name>
    <phone>00441223586796</phone>
    <email>dj106@cam.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rona M Smith, MA MRCP</last_name>
    <phone>00441223217259</phone>
    <email>ronasmith@doctors.net.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Addenbrooke's Hospital, University of Cambridge NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB20QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David RW Jayne, MD FRCP</last_name>
      <phone>00441223586796</phone>
      <email>dj106@cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>David RW Jayne, MD FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <last_update_submitted>July 28, 2011</last_update_submitted>
  <last_update_submitted_qc>July 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr David Jayne</name_title>
    <organization>Cambridge University Hospitals NHS Foundation Trust</organization>
  </responsible_party>
  <keyword>Vasculitis</keyword>
  <keyword>ANCA</keyword>
  <keyword>Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

